心力衰竭药物治疗中的性别差异
1Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
Ewha medical journal
|July 24, 2025
概括
性差异影响心力衰竭 (HF) 药物疗效和副作用. 考虑到这些生物变异的个性化治疗策略对于改善HF药物治疗患者的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 精准医学是一门精准的医学.
背景情况:
- 心力衰竭 (HF) 带来了重大的公共卫生挑战,高发病率和死亡率.
- 目前对高血压的药理管理在解决与性别相关的差异方面存在局限性.
- 在了解生物性别如何影响HF治疗结果方面存在差距.
研究的目的:
- 审查和澄清性别对HF药物的临床结果的影响.
- 要突出药物反应和HF患者的不良影响的性别特异性差异.
- 强调需要在HF药物治疗中采用性别知情方法.
主要方法:
- 临床试验和相关研究的系统审查.
- 对数据的分析,重点是基于性别的HF药物疗效差异.
- 对按性别分层的不良事件概况的检查.
主要成果:
- 在药物反应和不良反应方面,在男性和女性之间观察到显著的差异.
- 有证据表明,目前的HF治疗可能对所有性别都不具有同等的有效性或安全性.
- 在各种研究中,高频药物治疗结果的性别特异性模式是显而易见的.
结论:
- 对HF药物治疗的细微,性别特定的方法至关重要.
- 需要在临床试验中增加女性的代表性.
- 根据生物性别量身定制HF治疗方法,进步了精准医学并改善了患者的护理.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Heart Failure Drugs: Inotropic Agents
728
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728


